InvestorsHub Logo
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

Re: osaffer post# 510

Monday, 03/13/2017 12:02:37 PM

Monday, March 13, 2017 12:02:37 PM

Post# of 625
You're preaching to the choir vis-á-vis Ocaliva. I'm bearish on the REGENERATE trial, and have said so numerous times.

On the other hand, newer and better FXR agonists do not seem to have the side-effect baggage that comes with Ocaliva. I'm bullish on ENTA's NASH compound, EDP-305. (I'm long ENTA.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ICPT News